Back to today’s briefing

Story perspectives

FDA Fast Tracks First IV Ketamine Treatment for Suicidal Ideation

8/23/2025

28 6

Summary

Story summary

The FDA granted "fast track" designation to NRX-100, an intravenous ketamine treatment for suicidal ideation on August 11, 2025.
Clinical trials indicate response rates between 55% and 63%.
If approved, NRX-100 would be the first FDA-approved IV ketamine for this purpose, providing a rapid intervention.
Monitoring and controlled administration are necessary to mitigate potential abuse and side effects.

1 of 1

Story summary

The FDA granted "fast track" designation to NRX-100, an intravenous ketamine treatment for suicidal ideation on August 11, 2025.
Clinical trials indicate response rates between 55% and 63%.
If approved, NRX-100 would be the first FDA-approved IV ketamine for this purpose, providing a rapid intervention.
Monitoring and controlled administration are necessary to mitigate potential abuse and side effects.